Neuromyelitis Optica Spectrum Disorder
📧 Sign up to get email alerts when something new happens for Neuromyelitis Optica Spectrum Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-08-16Clinical Trial Update: A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients [Phase 1, Phase 2]
This clinical trial update describes an early-phase (Phase 1/2) study evaluating IMC-002 in neuromyelitis optica spectrum disorder, with the…
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 2]
A Phase 2 clinical trial evaluating mitoxantrone hydrochloride liposome injection for Neuromyelitis Optica Spectrum Disorder has completed, …
-
CLINICAL_TRIALS research · 2024-08-07Clinical Trial Update: Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
Sun Yat-Sen Memorial Hospital is conducting a cohort study of CNS idiopathic inflammatory demyelinating diseases and is currently recruiting…
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack [Phase 2]
Phase 2 clinical trial evaluating the FcRn antagonist efgartigimod for acute neuromyelitis optica spectrum disorder attacks is listed as not…
-
CLINICAL_TRIALS research · 2024-06-05Clinical Trial Update: National, Multicentric Registry Study on Neuroimmunological Diseases in China
National multicentric registry in China studying neuroimmunological diseases is currently recruiting, covering conditions such as Multiple S…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-05-28FDA Approved: BKEMV — Original Application (Amgen Inc)
FDA approved BKEMV (eculizumab-aeeB), a biosimilar to eculizumab, developed by Amgen. The approval covers the same indications as the refere…
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder [Phase 2]
Phase 2 trial evaluating bortezomib as add-on therapy for relapsing neuromyelitis optica spectrum disorder completed.
-
CLINICAL_TRIALS trial_result · 2023-08-09Clinical Trial Update: An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD [Phase 3]
Phase 3 trial of ravulizumab in adults with neuromyelitis optica spectrum disorder has completed, with results posted.
-
CLINICAL_TRIALS research · 2023-06-09Clinical Trial Update: Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder [Phase 4]
A Phase 4 trial update evaluating azathioprine metabolite concentrations and cytokine levels in neuromyelitis optica spectrum disorder.
-
FDA approval · 2022-09-14FDA Approved: ENSPRYNG — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for ENSPRYNG (satralizumab) submitted by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2022-08-23Clinical Trial Update: An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients [Phase 3]
Open-label extension of eculizumab in relapsing neuromyelitis optica shows continuing assessment in a Phase 3 study.
-
FDA approval · 2021-05-03FDA Approved: ENSPRYNG — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for ENSPRYNG (satralizumab) from Genentech, potentially updating its labeling or expanding its i…
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]
A Phase 3 trial evaluated satralizumab as monotherapy for neuromyelitis optica and NMOSD, with completed status and results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) [Phase 4]
Phase 4 trial update evaluating low-dose rituximab for neuromyelitis optica spectrum disorder has been completed.
-
CLINICAL_TRIALS trial_result · 2020-09-30Clinical Trial Update: Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients [Phase 2, Phase 3]
A completed Phase 2/3 trial comparing azathioprine and rituximab in neuromyelitis optica spectrum disorder.
-
FDA approval · 2020-08-14FDA Approved: ENSPRYNG — Original Application (Genentech, Inc.)
The FDA approved ENSPRYNG (satralizumab) from Genentech as the original application for the treatment of neuromyelitis optica spectrum disor…
-
FDA approval · 2020-06-11FDA Approved: UPLIZNA — Original Application (Horizon Therapeutics USA, Inc.)
FDA approved UPLIZNA (inebilizumab) in an original application for the treatment of neuromyelitis optica spectrum disorder.
-
CLINICAL_TRIALS trial_result · 2019-08-22Clinical Trial Update: Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders [Phase 2]
Phase 2 clinical trial comparing immunoadsorption versus plasma exchange for acute attacks in refractory neuromyelitis optica spectrum disor…
-
FDA approval · 2019-06-27FDA Approved: SOLIRIS — Supplemental Application (Alexion Pharmaceuticals Inc.)
The FDA approved a supplemental application for SOLIRIS (eculizumab) filed by Alexion Pharmaceuticals Inc., updating labeling to reflect the…
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) [Phase 3]
Phase 3 randomized trial of eculizumab in AQP4 antibody-positive neuromyelitis optica spectrum disorder was terminated; results posted in 20…
-
CLINICAL_TRIALS trial_result · 2019-06-06Clinical Trial Update: Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses [Phase 1]
Phase 1 trial update evaluating ublituximab for relapses in neuromyelitis optica and related spectrum disorders; results posted after comple…
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Central Pain Study for ABX-1431 [Phase 1]
Phase 1 central pain study of ABX-1431 conducted by Abide Therapeutics has completed.
-
CLINICAL_TRIALS research · 2018-05-02Clinical Trial Update: Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China
Clinical registry study update on Neuromyelitis Optica Spectrum Disorder in China, sponsored by Beijing Tongren Hospital.
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. [Phase 2]
Phase II trial of NPB-01 in anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder has completed; the document’s wording …
-
CLINICAL_TRIALS research · 2016-09-07Clinical Trial Update: The French Multiple Sclerosis Registry
This entry notes an update to the French Multiple Sclerosis Registry, run by Hospices Civils de Lyon, covering multiple sclerosis and neurom…